COMP <GO>
ATRC vs NVST // RSI-14 & 200D SMA MOMENTUM
AtriCure Inc. (NASDAQ) VS. Envista Holdings Corporation (NYSE) • 15-METRIC TALLY: ATRC 4
— NVST 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ATRC
LAST: $59.88 (-2.24%) • MKT CAP: $3.12B
rsi-technicals
60.6
LAST: $24.71 (+5.10%) • MKT CAP: $3.78B
rsi-technicals
47.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRC VS. NVST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATRC | NVST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.00% | 54.70% | +20.30 | ATRC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.90% | 5.10% | -7.00 | NVST | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.52% | 5.83% | -4.31 | NVST | /fcf-yield <GO> |
| Operating Margin | -1.80% | 7.90% | -9.70 | NVST | /operating-margins <GO> |
| Net Profit Margin | -2.10% | 1.70% | -3.80 | NVST | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 8.30% | +6.60 | ATRC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.08 | 1.61 | +10.47 | ATRC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | NVST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 60.6 | 47.2 | +13.40 | ATRC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.93 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 78.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.12B | $3.78B | -$660.6M | NVST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATRC REV | NVST REV | ATRC GROSS % | NVST GROSS % | ATRC FCF | NVST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $534.5M | $2.72B | 75.0% | 54.7% | $48.3M | $230.4M |
| FY 2024 | $465.3M | $2.51B | 74.7% | 54.7% | $745.0K | $302.7M |
| FY 2023 | $399.2M | $2.57B | — | — | $4.5M | $160.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRC // BETA —
NVST // BETA 0.93